Bladder cancer is a cancer that forms in tissues ... duplication and immune exhaustion with tumor progression. Detecting FGFR3-mutant muscle-invasive and metastatic urothelial cancers (MIBC ...

Pathogenic activating mutations in the fibroblast growth factor receptor 3 (FGFR3) drive disease maintenance and progression in urothelial cancer. 10-15% of muscle-invasive and metastatic urothelial ...

PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The global premature ejaculation treatment market size is estimated to grow by USD 1.53 billion from 2025 to 2029, according ...

CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target ...

The FDA has granted clearance to an investigational new drug (IND) application to initiate a phase 2 trial of TYRA-300 in patients with FGFR3-altered low-grade, intermediate-risk non-muscle invasive ...

The FDA cleared the investigational new drug (IND) application for TYRA-300 in low-grade, intermediate-risk non–muscle-invasive bladder cancer (NMIBC). TYRA-300 is an investigational, oral, ...

Joshi, MD, MPH. A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key ...

FGFR3 is the most frequently altered gene in ... "For the last thirty years, I have dedicated my career to helping patients with bladder cancer as a urologic oncologist, a principal investigator ...

FGFR3 is the most frequently altered gene in NMIBC ... "For the last thirty years, I have dedicated my career to helping patients with bladder cancer as a urologic oncologist, a principal investigator ...

intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The investigational drug TYRA-300 is a selective inhibitor designed specifically to target FGFR3 mutations, which are commonly ...